Skip to main content

Companion Diagnostics Market: Trends and Forecast

Page 1

Healthcare · Biotechnology · Investor Briefing

Companion Diagnostics Market A precision-medicine enabler pairing biomarker-led testing with targeted therapeutics — a USD 9 billion opportunity reshaping oncology, neurology, and beyond.

Market sizing · 2019–2030 outlook

2019 base

2030 forecast

CAGR · 2020–2030

14.8%

USD 1.96 USD 9.02 Bn

Bn

Global companion diagnostics revenue

Projected compound annual growth

Projected market size by 2030

By technology

By indication

Immunohistochemistry

PCR

In-situ Hybridization

Others

NGS

Oncology

Others

Europe

APAC

Geography span

N. America

Companion Diagnostics Market · Strategic outlook 2020–2030

Neurology

RoW

Source: Next Move Strategy Consulting · Dec 2025


Section 02 · Where growth comes from

Growth drivers & regional opportunities Demand is converging from four fronts: precision-medicine adoption, targeted-therapy pipelines, rising chronicdisease burden, and FDA momentum — with regional rotation toward Asia-Pacific unlocking the fastest 2020– 2030 expansion. Demand drivers

Regional opportunity map

Personalized & targeted therapy adoption

01

Payers and providers now require biomarker evidence before prescribing high-cost therapeutics.

Rising cancer & chronic-disease prevalence WHO: 1 in 6 deaths globally are cancer-related; 6.8M deaths annually from neurological disorders.

High sensitivity & fast turnaround time (TAT) reduce hospitalisation cost per treatment cycle.

Status

Europe

Mature

Region

Asia-Pacific

Top CAGR

Highest forecast CAGR — driven by China, India, Japan.

04

~60 FDA-cleared or approved CDx assays cumulatively; NGS-based tests cross 18% of approvals.

Lead

Mature markets; UK, Germany, France anchor.

03

FDA approval momentum & R&D investment

North America

Dominant today — established labs, R&D depth, payer reimbursement.

02

Speed, accuracy, and cost-effectiveness of CDx tests

Region

Rest of World

Emerging

UAE, Saudi, Brazil, S. Africa.

Clinical impact

Right drug. Right patient. Right time.

04 Demand drivers · 04 regions

CDx identifies patients most likely to benefit, suffer adverse events, or require dose adjustments — de-risking high-value therapeutics and accelerating reimbursement approvals.

Source: Next Move Strategy Consulting · Dec 2025


Section 03 · Who's leading

Competitive landscape A concentrated field of 10 anchor competitors — differentiated by technology stack, biopharma partnerships, and breadth of FDA-cleared assays. Scale players are extending lead via M&A and co-development with drug sponsors.

10

~60

18%+

Why consolidation matters

Anchor competitors

FDA-cleared / approved

Of approvals are NGS-

biopharma co-development pipelines —

profiled

CDx assays

based

Anchor players pair broad CDx menus with share follows scale.

Featured competitors

Roche

Thermo Fisher

Abbott

Qiagen

Agilent

Ventana Medical Systems

Life Tech & Oncomine Dx

Abbott Molecular

Qiagen N.V.

Dako Denmark

Danaher

bioMérieux

Myriad Genetics

ARUP Labs

Leica Microsystems

BioMérieux SA

Foundation Medicine

Roche affiliate (2018 acquisition)

Myriad Genetics, Inc.

ARUP Labs, Inc.

Key strategic moves

Play 01

Play 02

Play 03

Co-development with pharma

Strategic JV extensions

M&A & scale acquisitions

Thermo Fisher + Janssen Biotech (Mar 2020). Multi-biomarker CDx for oncology.

10 anchor competitors · 3 strategic moves

Roche / Foundation Medicine ~ $2.4B. Consolidated oncology CDx leadership. Thermo Fisher + Agios (Jun 2020). Global CDx for IDH-mutated glioma.

Source: Next Move Strategy Consulting · Dec 2025


Section 04 · Where to lean in

Strategic outlook & investment thesis Three structural theses frame the 2020–2030 opportunity. Two well-known constraints bound the upside. Watch the catalyst list for early signals on which players capture share next.

Forward theses

Thesis 01

Thesis 02

Thesis 03

NGS becomes the default platform

Pharma-CDx co-development at scale

Asia-Pacific takes share (highest CAGR)

Pan-cancer assays replace singlegene tests.

Therapy launches ship with diagnostic built-in.

China, India, Japan set the next decade.

NGS-based CDx already span 18%+ of FDA approvals — a structural shift toward one assay, many therapy decisions.

Drug sponsors now contract CDx partners pre-launch — biopharma pipeline becomes the pull-through, not the lab.

Improving infrastructure, medical tourism, and a chronic-disease demographic shift regional growth from follower to category leader.

Constraint register

Two known risks bound the upside i

What moves the next leg up

Costly R&D & validation burden Each new CDx must clear regulatory and clinical-validation gates — long cycles, large capex, and high failure risk per asset.

ii

Catalysts to watch

01

02

Liquid biopsy & ctDNA CDx clearing regulatory milestones.

03

FDA down-classification to Class II shortening launch cycles.

04

M&A consolidation among mid-cap diagnostic-platform players.

Reimbursement & payer variability Unfavorable coverage policies outside oncology slow diffusion — payer clarity is the gating lever for non-cancer indications.

03 theses · 02 risks · 04 catalysts

Pan-cancer companion approvals expanding beyond NSCLC & breast cancer.

Source: Next Move Strategy Consulting · Dec 2025


Section 05 · Let's connect

Thank you. In-depth strategic guidance, custom data cuts, and bespoke advisory — a direct line to Next Move Strategy Consulting.

Official website

Direct line

Inbox us

nextmsc.com

+1 857 758 5017

info@nextmsc.com

Reports, custom research, executive briefings.

Speak with our analyst team in business hours.

Briefings, sample reports, and procurement.

Get the complete report

See the full report

Full 300-page briefing · 163 tables · 133 figures nextmsc.com/report/companion-diagnostics-market

Visit nextmsc.com to unlock the full Companion Diagnostics Market report.

Follow us

Track healthcare, biotech, and diagnostics research as it lands. in

LinkedIn

Next Move SC

f

Facebook

YouTube

Next Move SC

@nextmsc

Companion Diagnostics Market · Investor Briefing

X

Twitter / X

Instagram

@nextmsc

@nextmsc

Copyright © Next Move Strategy Consulting


Turn static files into dynamic content formats.

Create a flipbook
Companion Diagnostics Market: Trends and Forecast by GYAN5566 - Issuu